tetano
Editor, Senior Moderator
Zhonghua Xue Ye Xue Za Zhi. 2012 Feb;33(2):113-6.
[The prognosis analysis of novel influenza A (H1N1) in patients with hematologic disease].
[Article in Chinese]
Gao Z, He XF, Zhang R.
Source
Department of Hematology, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Key Lab of Thrombosis and Hemostasis of ministry of Health, Suzhou 215006, China.
Abstract
OBJECTIVE:
To explore disease progression and prognosis factors of novel influenza A (H1N1) in immunocompromised patients with or without hematologic disease.
METHOD:
A total of 76 confirmed novel influenza A (H1N1) infection patients from November 2009 to March 2010 included in the study, their clinical feature was analyzed, and the relationship between clinical feature and outcome was explored retrospectively by multivariate analysis method.
RESULTS:
The whole 76 patients were administrated of oseltamivir. Among the 76 patients, 46 were severe and 23 were critical. Of the 6 patients with immunocompromised hematologic disease, 2 were severe and 4 were critical, case-fatality rate was 66.67% (4/6). The case-fatality rate of patients with non-hematologic disease was 10.42% (5/48). Multivariable logistic-regression analysis showed that immunocompromised hematologic disease (P = 0.0008, odds ratio:75.368; 95% CI, 5.980 to 949.853) and age (P = 0.0380) were independent risk factors for death. And other variables such as chronical lung disease, interval time from the onset of illness and lymphocyte count had no statistical signigicance (P > 0.05).
CONCLUSIONS:
The novel influenza A (H1N1) patients with immunocompromised hematologic disease has a poor prognosis, they can deteriorate quickly and have high mortality, it may aid clinicians to pay high attention to these people.
PMID:
22730660
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22730660
[The prognosis analysis of novel influenza A (H1N1) in patients with hematologic disease].
[Article in Chinese]
Gao Z, He XF, Zhang R.
Source
Department of Hematology, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Key Lab of Thrombosis and Hemostasis of ministry of Health, Suzhou 215006, China.
Abstract
OBJECTIVE:
To explore disease progression and prognosis factors of novel influenza A (H1N1) in immunocompromised patients with or without hematologic disease.
METHOD:
A total of 76 confirmed novel influenza A (H1N1) infection patients from November 2009 to March 2010 included in the study, their clinical feature was analyzed, and the relationship between clinical feature and outcome was explored retrospectively by multivariate analysis method.
RESULTS:
The whole 76 patients were administrated of oseltamivir. Among the 76 patients, 46 were severe and 23 were critical. Of the 6 patients with immunocompromised hematologic disease, 2 were severe and 4 were critical, case-fatality rate was 66.67% (4/6). The case-fatality rate of patients with non-hematologic disease was 10.42% (5/48). Multivariable logistic-regression analysis showed that immunocompromised hematologic disease (P = 0.0008, odds ratio:75.368; 95% CI, 5.980 to 949.853) and age (P = 0.0380) were independent risk factors for death. And other variables such as chronical lung disease, interval time from the onset of illness and lymphocyte count had no statistical signigicance (P > 0.05).
CONCLUSIONS:
The novel influenza A (H1N1) patients with immunocompromised hematologic disease has a poor prognosis, they can deteriorate quickly and have high mortality, it may aid clinicians to pay high attention to these people.
PMID:
22730660
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22730660